Drägerwerk reports weaker EBIT. Drägerwerk stock sits 22.97 percent below its 52-week high

Published on 10/19/2026 at 10:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 EBIT fell to EUR 48.00 million on October 14, 2026. Drägerwerk stock costs EUR 96.60 on October 19, 2026, 0.94 percent above EUR 95.70 Xetra close.

Quarterly pressure meets safety demand

Third-quarter EBIT fell to EUR 48.00 million from EUR 56.70 million on October 14, 2026.
Order intake reached EUR 926.00 million in the third quarter of 2026 versus EUR 856.10 million a year earlier.
Drägerwerk stock trades at EUR 96.60 at 10:29 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.94 percent above the Xetra close of October 16, 2026.
The full third-quarter statement is scheduled for October 29, 2026.

Makroaufnahme eines Gassensor-Schaltkreises mit goldenen Kontakten und elektrochemischen Zellen — Drägerwerk AG & Co. KGaA Makroaufnahme Gassensor Platine Sicherheitstechnik Elektronik Detail DE0005550636, Illustration mit AI erstellt.

Drägerwerk (ISIN DE0005550636) was trading at EUR 96.60 at Lang & Schwarz on October 19, 2026 at 10:29 a.m. CEST. In preliminary third-quarter figures dated October 14, 2026, BÖRSE ONLINE reported that EBIT fell to EUR 48.00 million from EUR 56.70 million a year earlier.

The figures put profitability ahead of the complete quarterly statement as the central issue for the stock. Drägerwerk's reported third-quarter EBIT margin was 5.60 percent, down from 6.80 percent, while the result included EUR 20.10 million in customs refunds, according to BÖRSE ONLINE.

Orders offer a counterweight

Revenue rose 2.10 percent to EUR 851.00 million in the third quarter of 2026, compared with EUR 833.30 million in the third quarter of 2025. Order intake grew 8.20 percent to EUR 926.00 million from EUR 856.10 million, giving the operating picture a stronger demand signal than the earnings line.

Safety Technology supplied the clearest contrast: its currency-adjusted order intake increased 20.20 percent to EUR 452.00 million, while Medical Technology order intake fell 3.00 percent to EUR 474.00 million. The company retained its 2026 outlook for currency-adjusted revenue growth of 2.00 to 6.00 percent and an EBIT margin of 6.00 to 8.00 percent, as stated in the BOERSE ONLINE release.

What must improve by October 29?

The answer is the conversion of demand into profit. Drägerwerk's first nine months of 2026 produced EUR 112.00 million of EBIT and a 4.60 percent margin, but customs refunds contributed EUR 27.90 million to that result, making cost control important for the final quarter.

The next reporting date is set

The full third-quarter statement is scheduled for October 29, 2026, giving investors a dated checkpoint for the preliminary figures, segment detail and the path toward the 2026 margin range. The company operates in medical and safety technology and reported approximately 16,700 employees on its Investor Relations page.

Stock stays below its yearly high

At EUR 96.60, the Lang & Schwarz price stood 22.97 percent below the 52-week high of EUR 125.40 and 46.36 percent above the 52-week low of EUR 66.00. The reference comparison is the Xetra close of October 16, 2026 at EUR 95.70.

The further course of trading is shown by the continuously updated real-time quote of Drägerwerk stock.